Completed PHASE4 INTERVENTIONAL 2-arm NCT00824564

Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Surgery For Long Bone Fracture

Prospective Randomized Phase IV Open Label Comparative Study Of Tranexamic Acid Plus Standard Of Care Versus Standard Of Care For The Reduction Of Blood Loss In Patients Undergoing Surgery For Long Bone Fracture

Sponsor: Pfizer

Conditions Femoral Fractures

Interventions Standard of care Tranexamic Acid plus standard of care

Updated 6 times since 2017 Last updated: Jun 6, 2011 Started: Apr 30, 2009 Primary completion: Jun 30, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00824564, this PHASE4 trial focuses on Femoral Fractures and remains completed. Sponsored by Pfizer, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Coimbatore, India